| Literature DB >> 28217251 |
Alexander Kaltenborn1, André Gutcke1, Jill Gwiasda1, Jürgen Klempnauer1, Harald Schrem1.
Abstract
AIM: To identify independent risk factors for biliary complications in a center with three decades of experience in liver transplantation.Entities:
Keywords: Biliary complications; Liver transplantation; Multivariable analyses; Prognostic model; Risk factors
Year: 2017 PMID: 28217251 PMCID: PMC5295148 DOI: 10.4254/wjh.v9.i3.147
Source DB: PubMed Journal: World J Hepatol
Clinical characteristics of recipient data
| MELD | 21 (11.5) | 18 (6-40) | |
| BMI | 24.2 (4.5) | 24.7 (15.1-40) | |
| Days on the waiting list | 277 (41.5) | 143 (0-4299) | |
| Male: Female | 915 (57%) to 692 (43%) | ||
| Age | 46.1 (12) | 47.5 (18-73.6) | |
| ICU stay in days | 23 (33) | 9 (1-276) | |
| Pre-transplant PVT | 143 (9) | ||
| Creatinine (μmol/L) | 121 (92) | 86 (38-707) | |
| Bilirubine (μmol/L) | 177 (209) | 72 (7-930) | |
| Indication HCC | 244 (15) | ||
| Indication PSC | 153 (9.5) | ||
| Indication ALF | 137 (8.5) | ||
| Indication HCV cirrh. | 101 (6.3) | ||
| Indication alc. cirrh. | 104 (6.4) | ||
| Indication biliary dis. | 326 (20.3) | ||
MELD: Model of End-Stage Liver Disease; BMI: Body mass index; ICU: Intensive care unit; PVT: Portal vein thromboses; HCC: Hepatocellular carcinoma; PSC: Primary sclerosing cholangitis; ALF: Acute liver failure; HCV: Hepatitis C virus.
Clinical characteristics of transplant specific data
| Gender mismatch | 929 (58) | ||
| Cold ischemic time (min) | 6.9 (220) | 593 (152-1696) | |
| Era 1 of transplantation | 303 (19) | ||
| Era 2 of transplantation | 434 (27) | ||
| Era 3 of transplantation | 453 (28) | ||
| Era 4 of transplantation | 417 (26) | ||
| > 1 arterial anastom. | 71 (4.5) | ||
| Aortal anastomosis | 164 (10.8) | ||
| Portal vein interpos. Graft | 14 (0.8) | ||
| Hepaticojejunostomy | 353 (22.4) | ||
| Post-transplant HAT | 59 (3.7) |
HAT: Hepatic artery thrombosis.
Clinical characteristics of donor data
| Age | 42 (16.9) | 43 (15-88) | |
| Male: Female | 969 (60%) to 624 (40%) | ||
| BMI | 24.8 (16.6) | 24 (20-44) | |
| Pre-transplant ICU stay | 8.7 (19.7) | 6 (1-383) | |
| Body temperature °C | 36.4 (1.0) | 36 (33-39) | |
| Bilirubine (μmol/L) | 12.5 (11.7) | 9.9 (0.9-154) | |
| Creatinine (μmol/L) | 96 (79) | 80 (12-885) | |
| CRP (mg/L) | 127 (108) | 114 (0.1-818) | |
| ALT (u/L) | 48 (190) | 22 (0-1136) | |
| AST (u/L) | 59 (2.67) | 29 (0-1074) | |
| GGT (u/L) | 51.2 (78.6) | 24 (0-912) | |
| Urea (mg/dL) | 7.2 (8.4) | 5.2 (0.2-103) | |
| CMV positivity | 805 (50) | ||
BMI: Body mass index; ICU: Intensive care unit; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Gamma glutamyltransferase; CMV: Cytomegalovirus; CRP: C-reactive protein.
Causes of death in transplanted patients over 30 years
| Sepsis | 109 (6.8) |
| Tumor recurrence | 103 (6.4) |
| 33 (2.1) | |
| Pneumonia | 31 (1.9) |
| Liver graft: Biliary complications | 20 (1.3) |
| Cardiovascular event | 18 (1.1) |
| Liver graft: Chronic rejection | 15 (0.9) |
| Cerebral ischemia | 12 (0.8) |
| Cerebral bleeding | 11 (0.7) |
| Liver graft: HCV reinfection | 11 (0.7) |
| Cerebral edema | 9 (0.6%) |
| Liver graft: HBV reinfection | 9 (0.6) |
| Gastrointestinal bleeding | 7 (0.4) |
| Gastrointestinal perforation | 6 (0.4) |
| Liver graft: Venous thrombosis | 6 (0.4) |
| Lung: Acute respiratory distress syndrome | 4 (0.3) |
| Polytrauma | 4 (0.3) |
| Cerebral infection | 3 (0.3) |
| Liver graft: HCV | 3 (0.3) |
| Liver graft: Initial non function | 3 (0.3) |
| Pulmonary embolism | 6 (0.4) |
| Gastrointestinal ischemia | 2 (0.1) |
| Liver graft: Arterial thrombosis | 2 (0.1) |
| Suicide | 2 (0.1) |
| Liver graft: Portal vein thrombosis | 1 (0.1) |
| Non-compliance to immunosuppression | 1 (0.1) |
| Recurrent alcoholism | 1 (0.1) |
| Unknown | 129 (8.1) |
| Total | 561 (35.1) |
HCV: Hepatitis C virus; HBV: Hepatitis B virus.
Figure 1Observed biliary complications as a percent of transplant per year over 30 years.
Figure 2Kaplan Meier curve showing the cumulative survival of (A) patients with and without biliary complications (B) graft survival of both groups.
Figure 3Different biliary complications in the Model of End-Stage Liver Disease era.
Univariable and multivariable analyses for identification of risk factors for anastomotic biliary complications since 2006
| Recipient data | MELD | 0.029 | 1.036 (1.003-1.050) | 0.006 | 1.035 (1.010-1.060) |
| BMI | 0.438 | ||||
| Days on the waiting list | 0.594 | ||||
| Gender | 0.494 | ||||
| Age | 0.752 | ||||
| ICU stay in days | 0.025 | 1.018 (1.001-1.012) | 0.093 | ||
| Pre-transplant PVT | 0.056 | ||||
| Creatinine | 0.042 | 1.003 (1.001-1.005) | |||
| Bilirubine | 0.034 | 1.001 (1.001-1.002) | |||
| Indication HCC | 0.328 | ||||
| Indication PSC | 0.415 | ||||
| Indication ALF | 0.620 | ||||
| Indication HCV cirrh. | 0.685 | ||||
| Indication alc. cirrh. | 0.769 | ||||
| Indication biliary dis. | 0.115 | ||||
| Transplant-specific data | Gender mismatch | 0.620 | |||
| Cold ischemic time | 0.417 | ||||
| Era of transplantation | 0.124 | ||||
| Preservation solution | 0.746 | ||||
| > 1 arterial anastom. | 0.396 | ||||
| Aortal anastomosis | 0.331 | ||||
| Portal vein interpos. Graft | 0.251 | ||||
| Hepaticojejunostomy | 0.425 | ||||
| Post-transplant HAT | 0.048 | 2.999 (1.010-8.056) | 0.019 | 3.543 (1.283-10.178) | |
| Operative duration | 0.624 | ||||
| Donor-specific data | Age | 0.738 | |||
| Gender male | 0.003 | 1.835 (1.050-3.303) | 0.066 | ||
| BMI | 0.014 | 0.923 (0.861-0.990) | 0.056 | ||
| Pre-transplant ICU stay | 0.115 | ||||
| Body temperature | 0.921 | ||||
| Bilirubine | 0.022 | 1.027 (1.005-1.050) | 0.073 | ||
| Creatinine | 0.020 | 1.003 (1.001-1.005) | 0.010 | 1.003 (1.001-1.006) | |
| CRP | 0.406 | ||||
| ALT | 0.765 | ||||
| AST | 0.613 | ||||
| GGT | 0.278 | ||||
| Urea | 0.581 | ||||
| CMV positivity | 0.100 | ||||
MELD: Model of End-Stage Liver Disease; BMI: Body mass index; ICU: Intensive care unit; ALT: Alanine aminotransferase; AST: Aspartate transaminase; GGT: Gamma glutamyltransferase; CMV: Cytomegalovirus; PVT: Portal vein thromboses; HCC: Hepatocellular carcinoma; PSC: Primary sclerosing cholangitis; ALF: Acute liver failure; HCV: Hepatitis C virus; CRP: C-reactive protein.
Figure 4Receiver operating characteristic-curve of the developed prognostic model for the prediction of anastomotic biliary complications in the Model of End-Stage Liver Disease-era (n = 417 liver transplants). The area under the receiver operating-curve is 0.702 indicating a useful and clinical applicable prognostic model.